The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic relevance of tumor sequencing in metastatic lung adenocarcinomas.
 
Ronglai Shen
No Relationships to Disclose
 
Axel Martin
No Relationships to Disclose
 
Ai Ni
No Relationships to Disclose
 
Matthew David Hellmann
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Novartis
Research Funding - Bristol-Myers Squibb
 
Emmet Jordan
No Relationships to Disclose
 
Arshi Arora
No Relationships to Disclose
 
Ryan Ptashkin
No Relationships to Disclose
 
Ahmet Zehir
No Relationships to Disclose
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca
 
Kathryn Cecilia Arbour
No Relationships to Disclose
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Harpoon Therapeutics; Seagen
 
Michael F. Berger
Research Funding - Illumina
 
David B. Solit
Honoraria - Loxo; Pfizer
Consulting or Advisory Role - Loxo; Pfizer
 
Venkatraman E. Seshan
No Relationships to Disclose
 
Maria E. Arcila
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Invivoscribe; Raindance Technologies
 
Marc Ladanyi
Honoraria - Merck (I)
Consulting or Advisory Role - NCCN/AstraZeneca; NCCN/Boehringer Ingelheim
Research Funding - Loxo (Inst)
 
Gregory J. Riely
Consulting or Advisory Role - Genentech
Research Funding - ARIAD (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme